EARNINGS RELEASE

2Q | 2026

August **12th,** 2026

Belo Horizonte, August 12th, 2026

Belo Horizonte, August 12, 2026 — Rede Mater Dei de Saúde ("Mater Dei" or "Company") (B3: MATD3) announces its results for the second quarter of 2026 (2Q26). Figures are presented on a consolidated basis in BRL million, unless otherwise indicated. Comparisons refer to the second quarter of 2025 (YoY comparisons) and the first quarter of 2026 (QoQ comparisons). Quarterly information follows Brazilian and International (IFRS) accounting rules and was audited by independent auditors.

Consolidated Figures

Financial Indicators (BRL million)	2Q26	2Q25	Δ	1Q26	Δ	6M26	6M25	Δ
Operational Beds (period average)	1,225	1,231	(0.5%)	1,168	+4.9%	1,197	1,199	(0.2%)
Patient-days (period total)	87,760	87,369	+0.4%	82,575	+6.3%	170,335	165,182	+3.1%
Occupancy Rate (period average)	78.7%	78.0%	+0.7pp	78.6%	+0.1pp	78.6%	76.1%	+2.5pp
Day Patient Occupancy Rate (average)	83.9%	83.0%	+0.9pp	84.3%	(0.4pp)	84.1%	81.4%	+2.7pp
Average Ticket (BRL MM/Bed)	2.87	2.55	+12.4%	2.86	+0.5%	2.86	2.59	+10.4%
Net Revenue	614	546	+12.4%	575	+6.7%	1,189	1,045	+13.7%
Gross Profit	187	165	+13.3%	174	+7.4%	361	309	+16.9%
Adjusted EBITDA	139	115	+20.3%	130	+6.6%	269	212	+26.8%
EBITDA Margin	22.6%	21.1%	+1.5pp	22.6%	-	22.6%	20.3%	+2.3pp
Adjusted Net Profit/Loss	45	27	+66.1%	36	+24.0%	81	47	+71.9%
Net Debt	763	772	-8	800	-37	763	772	-8
Net Debt (ex-buybacks, dividends)/EBITDA LTM	1.5x	1.6x	(0.1x)	1.6x	(0.1x)	1.5x	1.6x	(0.1x)

Quarterly Highlights

Operational and Financial

Consolidated
- ✓ Consolidated Quarterly Net Revenue and Adjusted EBITDA record
- ✓ Highest quarterly average ticket in the Network, up 12.4% vs. 2Q25
- ✓ 6.3% increase in patient-days and 4.9% increase in operational beds vs. 1Q26
- ✓ Net debt improves by R$37 million in the quarter.

RMBH (Belo Horizonte Metropolitan Region)
- ✓ 10% growth in Net Revenue vs. 2Q25
- ✓ Nova Lima with a 25% increase in oncology patients vs. 1Q26

Salvador:
- ✓ Record Net Revenue, with 30% growth vs. 2Q25
- ✓ 133% increase in oncology patients and 12% increase in surgical notices vs. 2Q25

Acquired:
- ✓ 1% growth in Net Revenue vs. 1Q26
- ✓ 109% increase in oncology patients and 6% increase in surgical notices vs. 2Q25
- ✓ HSG, EMEC, and Goiânia achieved the highest quarterly Net Revenue in history

Bradesco Health Plan Accreditation in Salvador

Rede Mater Dei de Saúde consolidates its relevance and expansion in Bahia by accrediting the newly launched Bradesco Saúde Efetivo Plus plan in the state at Hospital Salvador. This strategic partnership strengthens the Company's presence in the regional corporate market and ensures new beneficiaries access to state-of-the-art medical infrastructure, driven by technological innovation, a highly specialized clinical staff, and the highest standards of safety and excellence in high-complexity hospital care.

Early Redemption of BRL 200 million in Debentures

On July 20, 2026, Rede Mater Dei executed the early redemption of the 2nd series of the 3rd issuance of debentures, totaling BRL 200 million. This measure reinforces our continuous commitment to financial discipline and efficient debt management.

Awards and Recognition

- Obtained **Top Performer ICU** seals at RMBH units, highlighting healthcare efficiency and resource optimization across the hospitals.
- Achieved International **Qmentum Platinum Certification** in Goiânia, becoming the first private hospital in Goiás to receive this seal for global standards of quality and patient safety.
- Certification of the Contorno and Santo Agostinho units as **Level 1 Teaching Hospitals** by the **Ministry of Health**, recognizing the institution's robustness in training healthcare professionals.

Revenue

Volume

Gross revenue is primarily composed of healthcare services provided, such as hospitalizations, surgeries, oncology, medical consultations, and exams, whether through health insurance operators, self-management plans, government entities, or private patients (out-of-pocket).

The second quarter of 2026 showed an average of 1,225 operational beds, an increase of 57 beds compared to 1Q26, driven by more favorable seasonality, the ongoing ramp-up of our units, and high occupancy rates in the first quarter that enabled bed expansion. The quarterly occupancy rate reached 83.9%, aligned with the established strategy, representing a 0.9 p.p. increase YoY and a 0.4 p.p. decrease QoQ.

Evolution of Average Operation Beds and Occupancy Rate



Compared to 1Q26, patient-day volume increased by 6.3%, while the average number of operational beds grew 4.9%, aligned with the Company's strategy of operating with a higher occupancy rate to drive operational efficiency. Compared to 2Q25, patient-day volume saw a slight increase of 0.4%, with a minor reduction of 0.5% in operational beds.

Number of Patient-Days and Average Ticket (BRL/patient-day)



Revenue

Consolidated Ticket and Revenue Breakdown

The consolidated average ticket price in 2Q26 increased by 12.4% and 0.5% compared to 2Q25 and 1Q26, respectively, reaching BRL 2.87 million per bed used. The year-on-year growth is attributable to an improved mix of specialties, procedures, and health plans, with an increase in oncology, surgical notices, and off-bed revenue; shift in hospital weighting with the ramp-up of Nova Lima and Salvador; and annual price adjustments with payors.



In 2Q26, gross revenue totaled BRL 688.5 million, up 12.9% YoY and 6.9% QoQ, highlighting the company's sustainable growth.

Gross revenue is mainly reduced by: (i) provision for claim denials; (ii) federal and municipal taxes levied on revenue; and (iii) canceled invoices.

BRL million	Consolidated							
	2Q26	2Q25	Δ 2Q25	1Q26	Δ 1Q26	6M26	6M25	Δ 6M25
Providers	641.3	565.2	13.5%	597.3	7.4%	1,238.5	1,082.5	14.4%
Private Patients	36.5	35.6	2.5%	37.0	-1.3%	73.5	69.5	5.7%
Other Revenues	10.7	9.0	18.6%	10.1	6.4%	20.8	18.3	13.9%
Gross Revenue	**688.5**	**609.9**	**12.9%**	**644.3**	**6.9%**	**1,332.8**	**1,170.2**	**13.9%**
Claim denials	(30.1)	(26.5)	13.3%	(28.0)	7.4%	(58.0)	(50.8)	14.2%
Taxes and deductions	(44.8)	(37.5)	19.3%	(41.4)	8.2%	(86.2)	(74.3)	16.0%
Net Revenue	**613.6**	**545.8**	**12.4%**	**575.0**	**6.7%**	**1,188.6**	**1,045.1**	**13.7%**

Costs

Cost of Provided Services

The cost of services provided consists mainly of materials and medications, personnel, medical service provision, depreciation and amortization, and maintenance and repairs.

In 2Q26, the cost of services rendered totaled BRL 426.9 million, representing 69.6% of net revenue, a decrease of 0.2 p.p. compared to both 2Q25 and 1Q26. These reductions were driven by cost dilution from higher revenues, primarily in personnel, even with an increase in math/medicine due to the greater relevance of oncology in the results.

Consequently, reported Gross Profit reached BRL 186.7 million, while gross margin reached 30.4%, as changes in cost of services directly impact margins.

BRL million	Consolidated							
	2Q26	**2Q25**	**Δ 2Q25**	**1Q26**	**Δ 1Q26**	**6M26**	**6M25**	**Δ 6M25**
Materials and medications	(170.2)	(147.2)	15.7%	(155.7)	9.3%	(325.9)	(276.9)	17.7%
% of net revenue	*27.7%*	*27.0%*	*0.7pp*	*27.1%*	*0.6pp*	*27.4%*	*26.5%*	*0.9pp*
Personnel	(116.5)	(106.2)	9.6%	(113.9)	2.3%	(230.3)	(210.4)	9.5%
% of net revenue	*19.0%*	*19.5%*	*(0.5pp)*	*19.8%*	*(0.8pp)*	*19.4%*	*20.1%*	*(0.7pp)*
Medical service provision	(66.7)	(57.4)	16.2%	(60.6)	10.0%	(127.3)	(112.5)	13.2%
% of net revenue	*10.9%*	*10.5%*	*0.4pp*	*10.5%*	*0.4pp*	*10.7%*	*10.8%*	*(0.1pp)*
Maintenance and conservation	(24.8)	(22.9)	7.9%	(24.2)	2.5%	(48.9)	(44.5)	10.0%
% of net revenue	*4.0%*	*4.2%*	*(0.2pp)*	*4.2%*	*(0.2pp)*	*4.1%*	*4.3%*	*(0.2pp)*
Depreciation and amortization	(21.4)	(22.0)	-2.8%	(21.1)	1.3%	(42.5)	(44.0)	-3.5%
% of net revenue	*3.5%*	*4.0%*	*(0.5pp)*	*3.7%*	*(0.2pp)*	*3.6%*	*4.2%*	*(0.6pp)*
Other costs	(27.4)	(25.3)	8.5%	(25.6)	7.1%	(53.0)	(48.2)	10.0%
% of net revenue	*4.5%*	*4.6%*	*(0.1pp)*	*4.5%*	*-*	*4.5%*	*4.6%*	*(0.1pp)*
Cost of services provided	**(426.9)**	**(381.0)**	**12.1%**	**(401.0)**	**6.4%**	**(827.9)**	**(736.5)**	**12.4%**
% of net revenue	*69.6%*	*69.8%*	*(0.2pp)*	*69.8%*	*(0.2pp)*	*69.7%*	*70.5%*	*(0.8pp)*
Gross Profit	**186.7**	**164.8**	**13.3%**	**173.9**	**7.4%**	**360.7**	**308.6**	**16.9%**
Gross Margin %	*30.4%*	*30.2%*	*0.2pp*	*30.2%*	*0.2pp*	*30.3%*	*29.5%*	*0.8pp*

Expenses

General, Administrative, and Other Expenses

General and administrative expenses consist mainly of personnel expenses, depreciation and amortization, and other back-office related activities.

In 2Q26, general and administrative expenses reached 12.3% of net revenue, a 0.2 p.p. reduction compared to both 2Q25 and 1Q26. These reductions are due to lower personnel expenses resulting from the dilution of revenue growth. Regarding net operating expenses, which mainly include provisions/reversals for legal claims, provisions for doubtful accounts, and equity method accounting, there was a 1.0 pp reduction compared to 1Q26 due to a more favorable performance in these items, outperforming previous quarters. Compared to the same quarter of the previous year, the variation refers to the write-off of accounts receivable in 2Q25 due to the lack of expectation of payment, for which there was already a provision for losses, without the same effect in the current quarter.

BRL million	Consolidated							
	2Q26	**2Q25**	**Δ 2Q25**	**1Q26**	**Δ 1Q26**	**6M26**	**6M25**	**Δ 6M25**
Personnel	(43.8)	(42.4)	3.1%	(43.1)	1.5%	(86.9)	(85.9)	1.2%
% of net revenue	*7.1%*	*7.8%*	*(0.7pp)*	*7.5%*	*(0.4pp)*	*7.3%*	*8.2%*	*(0.9pp)*
Depreciation and amortization	(8.0)	(5.2)	52.6%	(7.8)	2.4%	(15.7)	(10.4)	50.6%
% of net revenue	*1.3%*	*1.0%*	*0.3pp*	*1.4%*	*(0.1pp)*	*1.3%*	*1.0%*	*0.3pp*
Third-party Services	(16.4)	(14.9)	9.4%	(15.1)	8.0%	(31.5)	(28.9)	8.9%
% of net revenue	*2.7%*	*2.7%*	*-*	*2.6%*	*0.1pp*	*2.7%*	*2.8%*	*(0.1pp)*
Other Expenses	(7.3)	(5.7)	29.3%	(5.7)	28.1%	(13.0)	(10.3)	26.9%
% of net revenue	*1.2%*	*1.0%*	*0.2pp*	*1.0%*	*0.2pp*	*1.1%*	*1.0%*	*0.1pp*
General and Adm. Expenses	**(75.4)**	**(68.3)**	**10.5%**	**(71.7)**	**5.1%**	**(147.1)**	**(135.5)**	**8.6%**
% of net revenue	*12.3%*	*12.5%*	*(0.2pp)*	*12.5%*	*(0.2pp)*	*12.4%*	*13.0%*	*(0.6pp)*
Other rev./exp. Operational	(2.1)	(8.6)	(75.8%)	(6.7)	(69.1%)	(8.8)	(15.8)	-44.4%
% of net revenue	*0.3%*	*1.6%*	*(1.3pp)*	*1.2%*	*(0.9pp)*	*0.7%*	*1.5%*	*(0.8pp)*
Net operating expenses	**(77.5)**	**(76.8)**	**0.8%**	**(78.4)**	**-1.2%**	**(155.9)**	**(151.3)**	**3.1%**
% of net revenue	*12.6%*	*14.1%*	*(1.5pp)*	*13.6%*	*(1.0pp)*	*13.1%*	*14.5%*	*(1.4pp)*

EBIT and EBITDA

Operating Result

Adjusted EBITDA reached BRL 138.6 million in 2Q26, an increase of 6.6% compared to 1Q26 and a significant 20.3% growth YoY. Adjusted EBITDA margin reached 22.6%, stable QoQ and up 1.5 p.p. YoY.

This growth was primarily driven by: (i) revenue growth through higher average tickets, volume expansion, and unit ramp-up, optimizing fixed cost dilution; and (ii) revisiting personnel lines through staff control.

BRL million	Consolidated							
	2Q26	**2Q25**	**Δ 2Q25**	**1Q26**	**Δ 1Q26**	**6M26**	**6M25**	**Δ 6M25**
Gross Revenue	**688.5**	**609.9**	**12.9%**	**644.3**	**6.9%**	**1,332.8**	**1,170.2**	**13.9%**
Taxes, deductions and claim denials	(74.8)	(64.1)	16.8%	(69.4)	7.9%	(144.2)	(125.1)	15.3%
Net Revenue	**613.6**	**545.8**	**12.4%**	**575.0**	**6.7%**	**1,188.6**	**1,045.1**	**13.7%**
Costs of provided services	(426.9)	(381.0)	12.1%	(401.0)	6.4%	(827.9)	(736.5)	12.4%
Net operational exp.	(77.5)	(76.8)	0.8%	(78.4)	-1.2%	(155.9)	(151.3)	3.1%
EBIT	**109.3**	**88.0**	**24.2%**	**95.5**	**14.4%**	**204.7**	**157.3**	**30.1%**
% of net revenue	*17.8%*	*16.1%*	*1.7pp*	*16.6%*	*1.2pp*	*17.2%*	*15.1%*	*2.1pp*
Depreciation and Amortization	29.3	27.2	7.9%	28.9	1.6%	58.2	54.5	6.9%
EBITDA	**138.6**	**115.2**	**20.3%**	**124.4**	**11.5%**	**262.9**	**211.8**	**24.2%**
% of net revenue	*22.6%*	*21.1%*	*1.5pp*	*21.6%*	*1.0pp*	*22.1%*	*20.3%*	*1.8pp*
Supplementary Provision for PS	-	-	-	5.6	(100.0%)	5.6	-	-
Adjusted EBITDA	**138.6**	**115.2**	**20.3%**	**130.0**	**6.6%**	**268.6**	**211.8**	**26.8%**
% of net revenue	*22.6%*	*21.1%*	*1.5pp*	*22.6%*	*-*	*22.6%*	*20.3%*	*2.3pp*



Net Financial Result

Financial Revenue and Expense

In the quarter, net financial income decreased by 4.0% compared to Q1 2026. The main highlights are: higher returns on financial investments and other financial income, in addition to a slight improvement in loan and financing interest expenses when added to the net effect of the swap.

Compared to Q2 2025, there was an 8.2% reduction in net financial income explained by lower loan interest expenses resulting from lower average gross debt in the period and lower average debt cost, as well as lower monetary correction of contingencies.

BRL million	Consolidated							
	2Q26	**2Q25**	**Δ 2Q25**	**1Q26**	**Δ 1Q26**	**6M26**	**6M25**	**Δ 6M25**
Financial Revenue	**28.4**	**29.9**	**-5.1%**	**25.8**	**10.1%**	**54.2**	**56.5**	**-4.0%**
Financial Expenses	**(71.0)**	**(76.3)**	**(7.0%)**	**(70.2)**	**1.2%**	**(141.2)**	**(142.0)**	**(0.6%)**
Interest on loans, financing, installments, and acquisitions	(47.5)	(50.3)	(5.6%)	(43.8)	8.4%	(91.3)	(93.8)	(2.7%)
Lease interest	(20.1)	(18.9)	6.4%	(19.9)	1.0%	(40.0)	(37.5)	6.5%
Others	(3.4)	(7.2)	(52.1%)	(6.5)	(46.9%)	(9.9)	(10.6)	(7.1%)
Net Financial Result	**(42.6)**	**(46.4)**	**(8.2%)**	**(44.4)**	**(4.0%)**	**(87.0)**	**(85.6)**	**1.7%**

Net Profit

In 2Q26, adjusted net profit reached BRL 45.0 million, representing a 66.1% YoY surge and a 24.0% QoQ increase. Net margin expanded to 7.3%, up 2.3 p.p. YoY and 1.0 p.p. QoQ. Net income expansion mirrors the operational growth factors detailed in the EBITDA section.



BRL million	Consolidated							
	2Q26	2Q25	Δ 2Q25	1Q26	Δ 1Q26	6M26	6M25	Δ 6M25
EBIT	109.3	88.0	24.2%	95.5	14.4%	204.7	157.3	30.1%
Net Financial Result	(42.6)	(46.4)	(8.2%)	(44.4)	(4.0%)	(87.0)	(85.6)	1.7%
EBT	**66.6**	**41.6**	**60.3%**	**51.1**	**30.4%**	**117.7**	**71.8**	**64.1%**
Income Tax and S.C.N.P	(21.7)	(14.5)	49.5%	(18.5)	16.9%	(40.2)	(24.5)	64.1%
Net Profit	**45.0**	**27.1**	**66.1%**	**32.6**	**38.1%**	**77.6**	**47.3**	**64.1%**
% of net revenue	*7.3%*	*5.0%*	*2.3pp*	*5.7%*	*1.6pp*	*6.5%*	*4.5%*	*2.0pp*
Supplementary Provision for PS	-	-	0.0%	3.7	-100.0%	3.7	-	-
Adjusted Net Profit	**45.0**	**27.1**	**66.1%**	**36.3**	**24.0%**	**81.3**	**47.3**	**71.9%**
% of net revenue	*7.3%*	*5.0%*	*2.3pp*	*6.3%*	*1.0pp*	*6.8%*	*4.5%*	*2.3pp*

Debt

At the end of 2Q26, Net Debt stood at BRL 763 million, a 4.6% reduction QoQ, driven by stronger operational cash flow. Compared to 2Q25, net debt decreased by 1.1%, even after absorbing the BRL 56 million acquisition of the remaining stake in Hospital Santa Clara in 4Q25. Financial Leverage (Net Debt / EBITDA LTM) dropped to 1.5x, down 0.1x vs. both 1Q26 and 2Q25, reflecting LTM EBITDA expansion.

Consolidated (BRL million)	2Q26	2Q25	Δ 2Q25	1Q26	Δ 1Q26
Short-Term Debt	114	79	44.4%	94	21.3%
Long-Term Debt	1,277	1,331	-4.0%	1,290	-1.0%
Gross Debt[1]	**1,391**	**1,410**	**-1.3%**	**1,384**	**0.5%**
Cash, cash equivalents, and financial investments	628	638	-1.6%	584	7.5%
Net Debt	**763**	**772**	**-1.1%**	**800**	**-4.6%**
EBITDA LTM[1]	516	484	6.7%	493	4.7%
Net Debt / EBITDA LTM	*1.5*	*1.6*	*-0.1*	*1.6*	*-0.1*

1. In accordance with the covenant of the Company's debenture issuances.

In order to show the evolution of the company's cash generation over recent quarters, we have prepared a hypothetical debt variation exercise excluding shareholder remuneration items (share buybacks and dividends – paid and received). Over the last 12 months, net debt would have decreased by BRL 82 million, while the leverage ratio in 1Q26 would stand at 1.3x. Below is a chart showing net debt (BRL million) and accumulated buybacks/dividends (BRL million):



The weighted average debt amortization term is 4.98 years (vs. 5.16 years in 1Q26). The cost of debt in 2Q26 was CDI - 0.81% p.a.





Excludes transaction costs.

Cash Flow

In 2Q26, operating cash flow before working capital reached BRL 135 million, with BRL 2 million consumed by working capital changes (receivables, suppliers, inventories). Net operating cash flow was further impacted by BRL 30 million in loan/lease interest payments (primarily debenture semi-annual commitments) and BRL 17 million in income tax and social contribution payments.

Investment activities consumed BRL 27 million, in alignment with disciplined CAPEX strategy. Other cash items had a negative net variation of BRL 6 million. Excluding share buybacks and acquisition payments, cash balances stood at BRL 638 million (+BRL 54 million in the quarter), demonstrating strong operational performance converting into cash generation.



*includes the effect of cash lease amortization

Key Perfomance Indicators LTM

CAGR	Δ quarterly
+12.1%	+2.9%
+2.4 p.p.	+0.6 p.p.
+26.0%	+6..0%
+50.1%	+10.7%

Financial Indicators (Jan/25 to Jun/26)

Net Debt — Trajectory (ex-IFRS, R$ million)



ROIC — Trajectory (%)

+359 bps (+50%) since 2024

R$189 M
Accumulated Net Income

R$238 M
Accumulated FCFE

126%
FCFE / Net Income — 18 months (Jan/25 to Jun/26)

ROIC: Debt in Current Liabilities adjusted for leases, accounts payable for acquisitions and redemption of shares. Assets adjusted for cash and cash equivalents, reimbursement for works and right-of-use assets.

Dívida Líquida ao FCFE



** FCFE = Δ Net Debt excluding the effects of Dividends + Buybacks + Acquisitions of Companies*

Appendix

P&L

(BRL thousand)	2Q26	2Q25	1Q26	6M26	6M25
Gross Revenue	**688,461**	**609,862**	**644,322**	**1,332,783**	**1,170,217**
Healthcare Operator	641,255	565,214	597,269	1,238,524	1,082,482
Out-of-pocket patients	36,480	35,602	36,975	73,455	69,467
Other revenue	10,726	9,046	10,078	20,804	18,268
Taxes and Deductions	**(74,828)**	**(64,055)**	**(69,364)**	**(144,192)**	**(125,092)**
Net Revenue	**613,633**	**545,807**	**574,958**	**1,188,591**	**1,045,125**
Costs of services provided	**(426,901)**	**(380,982)**	**(401,037)**	**(827,938)**	**(736,512)**
Medical Supplies and drugs	(170,198)	(147,156)	(155,683)	(325,881)	(276,912)
Personnel	(116,454)	(106,245)	(113,881)	(230,335)	(210,434)
Medical services	(66,696)	(57,401)	(60,619)	(127,315)	(112,475)
Maintenance and conservation	(24,766)	(22,945)	(24,153)	(48,919)	(44,481)
Depreciation and amortization	(21,378)	(21,984)	(21,101)	(42,479)	(44,018)
Other costs	(27,409)	(25,251)	(25,600)	(53,009)	(48,192)
Gross profit	**186,732**	**164,825**	**173,921**	**360,653**	**308,613**
General and administrative expenses	**(75,398)**	**(68,256)**	**(71,733)**	**(147,131)**	**(135,490)**
Personnel	(43,762)	(42,434)	(43,099)	(86,861)	(85,856)
Depreciation and amortization	(7,958)	(5,214)	(7,775)	(15,733)	(10,446)
Third-party services	(16,356)	(14,947)	(15,145)	(31,501)	(28,916)
Other expenses	(7,322)	(5,661)	(5,714)	(13,036)	(10,272)
Equity pickup	**256**	**(31)**	**94**	**356**	**(1,259)**
Other operating income (expenses)	**(2,332)**	**(8,542)**	**(6,807)**	**(9,145)**	**(14,554)**
Earnings before financial income and expenses	**109,258**	**87,996**	**95,475**	**204,733**	**157,310**
Financial revenue	28,393	29,909	25,788	54,181	56,452
Financial expenses	(71,014)	(76,328)	(70,169)	(141,183)	(142,011)
Net financial result	**(42,621)**	**(46,419)**	**(44,381)**	**(87,002)**	**(85,559)**
Earnings before income tax and social contribution	**66,637**	**41,577**	**51,094**	**117,731**	**71,751**
Income Tax and Social Contribution	**(21,650)**	**(14,486)**	**(18,528)**	**(40,178)**	**(24,487)**
Net Income / (Loss) for the period	**44,987**	**27,091**	**32,566**	**77,553**	**47,264**
Supplementary Provision for PS	-	-	3,703	3,703	-
Adjusted Net Profit for the period	**44,987**	**27,091**	**36,269**	**81,256**	**47,264**
				-	
Profit attributable to controlling shareholders	**44,245**	**26,235**	**33,205**	**77,450**	**46,166**
Profit attributable to non-controlling shareholders	**742**	**856**	**(639)**	**103**	**1,098**
				-	

(BRL thousand)	2Q26	2Q25	1Q26	6M26	6M25
EBIT	**109,258**	**87,996**	**95,475**	**204,733**	**157,310**
Depreciation and amortization	29,336	27,198	28,876	58,212	54,464
EBITDA	**138,594**	**115,194**	**124,351**	**262,945**	**211,774**
Supplementary Provision for PS	-	-	5,610	5,610	-
Adjusted EBITDA	**138,594**	**115,194**	**129,961**	**268,555**	**211,774**

Appendix

Balance Sheet

(BRL thousand)	06/30/2026	06/30/2025	12/31/2025
Assets			
Current			
Cash and Cash Equivalents	599,902	613,537	599,130
Financial Investments	27,928	24,676	26,328
Accounts receivable	770,137	724,418	717,064
Inventories	75,387	53,674	71,785
Construction Reimbursement	44,128	42,248	43,195
Other current assets	43,181	40,963	36,591
Total current assets	**1,560,663**	**1,499,516**	**1,494,093**
Non-current			
Construction Reimbursement	242,703	274,563	259,168
Judicial deposits	63,906	53,881	60,666
Deferred taxes	235,189	224,820	234,266
Investments	10,879	12,174	11,506
Right of use	680,152	676,384	665,852
Fixed Assets	797,835	816,386	811,604
Intangible Assets	729,605	731,672	730,498
Other non-current assets	59,457	49,273	45,236
Total non-current assets	**2,819,726**	**2,839,153**	**2,818,796**
Total Assets	**4,380,389**	**4,338,669**	**4,312,889**
Liabilities			
Current			
Suppliers	151,841	127,990	148,566
Loans and financing	111,041	76,731	112,332
Derivatives	3,156	2,351	2,599
Leasing	81,544	70,547	78,371
Salaries & social security contribution	77,776	79,486	66,891
Taxes and contributions payable	40,255	31,713	38,519
Installment payment of taxes	102	2,196	338
Accounts payable of company acquisition	68,326	27,518	30,761
Redemption liability	2,383	58,369	2,383
Other current liabilities	7,550	8,109	10,346
Total current liabilities	**543,974**	**485,010**	**491,106**
Non-current			
Loans and financing	1,253,843	1,311,259	1,290,122
Derivatives	23,145	19,592	20,361
Leasing	721,584	703,827	698,427
Installment payment of taxes	508	649	508
Deferred taxes liabilities	114,226	77,394	74,362
Accounts payable of company acquisition	86,199	140,079	141,639
Provision for contingencies	121,562	111,071	110,241
Other non-current liabilities	8,060	8,756	8,549
Total non-current liabilities	**2,329,127**	**2,372,627**	**2,344,209**
Equity Capital			
Capital	1,301,019	1,301,019	1,301,019
Capital reserves	219,222	211,047	140,898
Income reserves	90,368	31,372	90,659
(-) Treasury stocks	(12,377)	(13,978)	(6,303)
Equity valuation adjustment	(105,414)	(77,667)	(61,785)
Total equity attributable to the Company's shareholder	**1,492,818**	**1,451,793**	**1,464,488**
Share of noncontrolling shareholders	14,470	29,239	13,086
Total Shareholders' equity	**1,507,288**	**1,481,032**	**1,477,574**
Total Liabilities	**4,380,389**	**4,338,669**	**4,312,889**

Appendix
Cash Flow

(BRL thousand)	06/30/2026	06/30/2025
Cash flow from operating activities		
Net profit for the period	77,553	47,264
Adjustments to reconcile net income to cash from operations		
Depreciation and amortization	58,212	54,464
Write-off of fixed and intangible assets	2,345	1,100
Establishment (reversal) of allowance for doubtful accounts	12,913	9,559
Establishment (reversal) of provision for disallowances	45,650	-9,200
Establishment (reversal) of provision and restatement for contingencies	-2,904	5,426
Share-Based Payment provision	874	2,628
Equity pickup gains	(350)	1,259
Derivative Gains	1,966	331
Income from financial investments	(36,669)	(39,982)
Net financial expenses	119,001	120,957
Provision for income tax and social contribution - current & deferred	(358)	2,923
	278,233	**196,729**
Variations in Operating Assets and Liabilities		
Accounts Receivable	(113,076)	(63,984)
Inventories	4,212	(3,253)
Other Assets	(2,084)	(625)
Judicial Deposits	1,856	352
Suppliers	3,818	(2,070)
Salaries and social security contributions	10,885	23,308
Taxes and contributions payable	35,405	18,693
Tax installments	(246)	(3,721)
Other liabilities	1,287	(962)
	(57,943)	**(32,263)**
Income tax and social contributions paid	(33,669)	(10,797)
Interest paid	(99,819)	(92,556)
Net cash generated by operating activities	**86,802**	**61,113**
Cash Flow of Investment activities		
Acquisition of fixed assets	(32,318)	(12,165)
Acquisition of intangible assets	(6,236)	(7,616)
Capital Contribution / AFAC	(471)	-
Acquisition of investments	(24,730)	(31,925)
Net financial investments	35,069	68,040
Net cash generated (used) in investment activities	**(28,686)**	**16,334**
Cash flow from financing activities		
Loans and financing	-	454
Payments of loans and financing	(34,621)	(38,973)
Lease payments	(14,283)	(11,919)
Derivative settlement	(2,809)	178
Treasury stocks	(6,074)	(21,458)
Dividends paid	443	(14,773)
Net cash provided by (used in) financing activities	**(57,344)**	**(86,491)**
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	**772**	**(9,044)**
Cash and cash equivalents at the beginning of the period	599,130	622,581
Cash and cash equivalents at the end of the period	599,902	613,537
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	**772**	**(9,044)**

Glossary and Other Information

AoP: Average of period

LTM: Last Twelve Months

IFRS 16: As of January 1st, 2019, all companies had to adapt to the new rules of IFRS 16, With this new standard, lessees now have to recognize the asset of rights over leased assets and the liability of future payments for medium or long-term leases, including operating leases, The biggest impact we had was on the real estate lease contracts of our operational and administrative units,

EBITDA: Earnings before Interest, Taxes, Depreciation and Amortization

EBITDA Margin: EBITDA divided by net revenue

EBIT: Earnings before Interest and Taxes

CDI: Interbank Deposit Certificate

Occupancy rate: Number of beds occupied by patients per day added up over a given period, divided by the number of beds that were operational each day added up during the same period.

About Rede Mater Dei de Saúde

Rede Mater Dei de Saúde is an integrated platform that provides hospital and cancer services, being a national reference in health and the largest private hospital network in Minas Gerais, The Company has more than 2,200 beds of capacity in its 9 units located in the metropolitan region of Belo Horizonte ("RMBH"), Salvador, Uberlândia, Goiânia and Feira de Santana,

Rede Mater Dei has a clinical expertise that is recognized by patients, medical community, healthcare operators, suppliers, and relevant sectors of the Brazilian Society, and focuses on innovation and medical pioneering,

Relationship with independent auditors

In accordance with CVM Resolution CVM 162/22, we inform that our policy for hiring independent auditors considers the best governance principles, which reserve the auditor's independence, in accordance with internationally accepted criteria,

For additional Investor Relations information, please access the website: https://ri,materdei,com,br/en/ or e-mail ri@materdei,com,br

This material contains summary information, which is not intended to be complete and should not be considered by shareholders or potential investors as an investment recommendation, Information about Mater Dei, its activities, economic and financial situation, and the risks inherent to its activities, as well as its financial statements, can be obtained on the world wide web, on the Mater Dei website (https://ri,materdei,com,br/en/)

HUB BRASIL CENTRAL
Mater Dei Goiânia
Goiânia/GO

Mater Dei Santa Clara
Uberlândia/MG

Mater Dei Santa Genoveva
Uberlândia/MG

Mater Dei CDI
Uberlândia/MG

SÃO PAULO
Mater Dei São Paulo
[Under Construction]

HUB BAHIA
Mater Dei Salvador
Salvador/BA

Mater Dei Emec
Feira de Santana/BA

HUB RMBH
Mater Dei Santo Agostinho
Belo Horizonte/MG

Mater Dei Contorno
Belo Horizonte/MG

Mater Dei Betim-Contagem
Betim/MG

Mater Dei Nova Lima
Nova Lima/MG